How effective is Tivozanib?

The U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor tivozanib for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have relapsed or are refractory to two or more prior systemic therapies. The approval is based on theTIVO-3 trial. The main efficacy outcome measure is progression-free survival (PFS). Other efficacy endpoints are overall survival (OS) and objective response rate (ORR). Patients need to take the drug until the disease worsens or unacceptable toxicity occurs. The results of the study showed that the median PFS, median OS, and ORR of the tivozanib group were 5.6 months and 16.4 months, respectively, and 18%. In patients with advanced renal cancer, tivozanib has a favorable safety profile, resulting in relatively low rates of dose reductions, treatment interruptions, or discontinuations.